Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,824.91
-9.9080-0.54%
Number of Gainers:2
Number of Losers:17
Number of Flat:- -
PE:- -
High:1,831.29
Open:1,830.64
Low:1,800.68
Close:1,834.82
Volume:57.96M
Turnover:4.48B
Market Cap:1.48T
Float Cap:1.45T

Loading ...

BioNTech CEO Uğur Şahin Disposes of USD 6,090,748 in Common Shares

Reuters
·
Sep 29

NanoViricides FY26 Net Loss Narrows 13% to $8.22 Million; Revenue Remains no Revenue

Reuters
·
Sep 29

Pfizer, Moderna Lose Bids to Escape Bayer US mRNA Patent Lawsuit

Reuters
·
Sep 29

Market Chatter: BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts

MT Newswires Live
·
Sep 29

AstraZeneca Advances Fixed-Dose Cholesterol Combo With Completed Phase I Bioavailability Study

TIPRANKS
·
Sep 29

AstraZeneca PLC Stock Rises Monday, Outperforms Market

Dow Jones
·
Sep 29

Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says

MT Newswires Live
·
Sep 28

BioNTech to Proceed with Site Closures After Failing to Find Buyer

Dow Jones
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

NanoViricides Starts Phase II DRC Trial of Oral NV-387 Gummies in Bundibugyo Ebola Patients

Reuters
·
Sep 28

Humacyte Adds Scott Coward to Board, Names Him to Audit Committee

Reuters
·
Sep 28

Xilio Therapeutics Names Yariv Houvras Chief Medical Officer

Reuters
·
Sep 28

Pfizer to Present Phase 3 SigVie-002 Survival Data for Sigvotatug Vedotin in Previously Treated NSCLC at ESMO 2026

Reuters
·
Sep 28

Berenberg Bank Sticks to Its Hold Rating for Bilfinger (0NRG)

TIPRANKS
·
Sep 28

Abbott Study Links CGM Use in Type 2 Diabetes Patients on Basal Insulin to 45% Lower 12-Month Mortality Risk

Reuters
·
Sep 28

Pfizer (PFE) Bets Big on RSV and Cancer Care

TIPRANKS
·
Sep 26

NYSE Most Active Issues

Dow Jones
·
Sep 26

NASDAQ New 52-Week Highs and Lows

Dow Jones
·
Sep 26

Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study

TIPRANKS
·
Sep 26

Pfizer’s RSV Revaccination Trial Targets Durable Booster Revenue in High‑Risk Adults

TIPRANKS
·
Sep 26